CymaBay Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $434.69 Mil.
During the past 12 months, CymaBay Therapeutics's average Total Assets Growth Rate was 535.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 75.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 19.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 32.20% per year.
During the past 12 years, CymaBay Therapeutics's highest 3-Year average Total Assets Growth Rate was 84.20%. The lowest was -24.50%. And the median was 38.00%.
The historical data trend for CymaBay Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
CymaBay Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics (NAS:CBAY) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
CymaBay Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
CymaBay Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of CymaBay Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
CymaBay Therapeutics (CymaBay Therapeutics) Business Description
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CBAY has been successfully added to your 